Results 241 to 250 of about 4,735,099 (379)

Plants: a tool box of cell-based assays

Nature Methods, 2016
V. Marx
semanticscholar   +1 more source

Investigation of the Potential Active Compounds in Selenium-Enriched Brassica Napus L. For Enhancing Mouse Sertoli Cell Viability Based on Uplc-Ms/Ms Analysis, Network Pharmacology and Cellular Assay

YiQing Lü, Xiaoli Fang, Xiaoling Dun, Xinfa Wang, Hanzhong Wang, Zhenna Chen   +5 more
openalex   +1 more source

Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBα

, 2018
Yuliya Hering, Alexandre Berthier, Hélène Duez, Philippe Lefèbvre, Benoît Déprez, Philip Gribbon, Markus Wolf, Jeanette Reinshagen, Francoise Halley, Juliane Hannemann, Rainer H. Böger, Bart Staels, Sheraz Gul   +12 more
openalex   +2 more sources

Galactomannan, β-D-Glucan, and Polymerase Chain Reaction–Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis [PDF]

, 2016
Thomas Lehrnbecher, Paula D. Robinson, Brian T. Fisher, Elio Castagnola, Andreas H. Groll, William J. Steinbach, Theoklis E. Zaoutis, Zelalem Negeri, Joseph Beyene, Bob Phillips, Lillian Sung   +10 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders. [PDF]

ACS Pharmacol Transl Sci
Kidane M, Hoffman RM, Wolfe-Demarco JK, Huang TY, Teng CL, Samanta S, Gonzalez Lira LM, Lin-Jones J, Pallares G, Lamerdin JE, Servant NB, Lee CY, Yang CT, Bernatchez JA.   +13 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Comparison of commercial and in-house tissue-based and cell-based assays for the detection of autoantibodies targeting neuronal surface proteins: a prospective cohort study. [PDF]

Front Immunol
Goncalves D, Benaiteau M, Rogemond V, Closs S, Pinto AL, Dhairi M, Villard M, Picard G, Fabien N, Honnorat J.   +9 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Performance of cryptogenic new onset refractory status epilepticus score in a Brazilian cohort after testing for antineuronal antibodies with tissue-based and cell-based assays. [PDF]

Epilepsia
Ferreira JHF, Gomes AM, Zetehaku AC, Marinho TF, Toso FF, Disserol CCD, Krueger MB, Santos MLSF, Juliano AFB, Barbosa TL, de Almeida Rocha LJ, Gameleira FT, Paolilo RB, Daccach V, Gomes JPI, Lin K, da Nóbrega AW, Marmentini EL, Fusão EF, de Cuffa A, Tavares GLA, Dias RM, Diniz SSL, Siquineli F, Braga-Neto P, Nobrega PR, Sanders LP, Carvalho FMM, Pereira RBR, de Melo ES, de Miranda Henriques-Souza AM, de Oliveira Godeiro C, Arambula OG, de Souza E Silva FN, Couto KO, Danieli D, Seitz KW, Dellavance A, Endmayr V, Höftberger R, Andrade LEC, Caboclo LO, Dutra LA.   +42 more
europepmc   +1 more source